• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current therapeutic research, clinical and experimental. >The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
【24h】

The Effects of Gliclazide, Metformin, and Acarbose on Body Composition in Patients with Newly Diagnosed Type 2 Diabetes Mellitus

机译：格列齐特，二甲双胍和阿卡波糖对新诊断的2型糖尿病患者身体成分的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Although numerous clinical trials have evaluated the body weight change achieved using diabetes medications alone or in combinations, the composition of body weight change in these clinical trials has rarely been assessed.Objective: We aimed to evaluate the effects of gliclazide, metformin, and acarbose monotherapy on body composition, fat distribution, and other cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes. Methods: A total of 86 patients with newly diagnosed type 2 diabetes mellitus were randomly assigned to receive gliclazide, metformin, or acarbose for 6 months. Dual-energy x-ray absorptiometry; abdominal computed tomography scans; and measurements of adiponectin, leptin, and lipid levels were performed before and after 6-month monodrug therapy. Results: Blood glucose and glycosylated hemoglobin levels significantly improved after 6 months of monodrug therapy. During the 6 months of use of the 3 antidiabetes medications, the majority of participants experienced fat mass loss and lean mass gain. Metformin monotherapy in patients with newly diagnosed type 2 diabetes led to a significant decrease in percent body fat (P = 0.029) and body fat mass (P = 0.038). Levels of serum total cholesterol (P = 0.004), triglycerides (P = 0.014), and adiponectin (P = 0.001) took a favorable turn after metformin treatment. The 3 antidiabetes medications caused no significant change in abdominal fat distribution, waist circumstance, and blood pressure during the 6 months. Conclusions: Our results suggest metformin therapy in patients with newly diagnosed type 2 diabetes can improve cardiometabolic risk markers. Moreover, body composition change induced by gliclazide and acarbose was not likely to be simple fat deposition.
机译：背景：尽管许多临床试验已经评估了单独或联合使用糖尿病药物所实现的体重变化，但很少评估这些临床试验中体重变化的组成。目的：我们旨在评估格列齐特，二甲双胍和盐酸格列齐特的疗效阿卡波糖单药治疗对初诊2型糖尿病患者的身体成分，脂肪分布和其他心脏代谢危险因素。方法：总共86例新诊断为2型糖尿病的患者被随机分配接受格列齐特，二甲双胍或阿卡波糖治疗6个月。双能X射线吸收法;腹部计算机断层扫描;在六个月的单药治疗之前和之后进行了脂联素，瘦素和脂质水平的测定。结果：单药治疗6个月后，血糖和糖基化血红蛋白水平显着改善。在使用3种抗糖尿病药物的6个月中，大多数参与者经历了脂肪量减少和瘦体重增加。在新诊断为2型糖尿病的患者中，二甲双胍单药治疗可显着降低体脂百分比（P = 0.029）和体脂质量（P = 0.038）。二甲双胍治疗后，血清总胆固醇（P = 0.004），甘油三酸酯（P = 0.014）和脂联素（P = 0.001）的水平出现良好变化。 3种抗糖尿病药物在6个月内未引起腹部脂肪分布，腰部情况和血压的明显变化。结论：我们的结果表明，二甲双胍治疗可用于新诊断的2型糖尿病患者，可改善心脏代谢风险指标。此外，格列齐特和阿卡波糖引起的身体成分变化不太可能是简单的脂肪沉积。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号